In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orion Pharma

Division of Orion Corp.
www.orion.fi

Latest From Orion Pharma

Orion Struggles To Make Headway With Rival To Seretide

A sluggish start to selling its salmeterol/fluticasone device in Europe did not prevent Finland’s Orion from growing its Easyhaler line of respiratory devices in the first half of 2019.

Respiratory Launches

Bayer Confident It Can Cope With Patent Cliff Pain

The German major noted that the effects of the losses of patent protection on Xarelto and Eylea are still about five years down the line and it expects to be able to soften the blow with some future big-earners from the pipeline and more external deals.

Sales & Earnings Strategy

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

This month a handful of biosimilars of the world’s top-selling drug, Humira (adalimumab), are due to launch in Europe. They will not topple the $18 billion behemoth. But they will do some damage, as Europe’s cash-strapped payers ready themselves to embrace these cheaper lookalikes. 

Biosimilars Market Intelligence

Pipeline Watch: Phase III Starts With QPI-1002, Enfortumab Vedotin And ZYN-002

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Finland
  • Parent & Subsidiaries
  • Orion Corp.
  • Senior Management
  • Jyrki Mattila, PhD, Pres.
  • Contact Info
  • Orion Pharma
    Phone: (358) 9 429 3325
    P.O. Box 65
    P.O. Box 65 Espoo, FIN-02101
    Finland
Advertisement
Advertisement
UsernamePublicRestriction

Register